Selected research
Market Outlook & Growth Opportunities
Global Opioid Analgesics Market Outlook and Growth Opportunities 2026
Market perspective
The global Opioid Analgesics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.
The North America market for Opioid Analgesics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Opioid Analgesics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Opioid Analgesics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
In China, the Opioid Analgesics market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Major global companies in the Opioid Analgesics market include Assertio Holdings, Inc, Bausch Health, Boehringer Ingelheim International GmbH, Endo International Plc, F. Hoffmann-La Roche AG, Purdue Pharmaceuticals L.P., Sanofi S.A., Teva Pharmaceuticals and Abbott Laboratories, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Opioid Analgesics market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Opioid Analgesics and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Opioid Analgesics sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Opioid Analgesics market size, projected growth trends, production technologies, key applications, and end-use industries.
Opioid Analgesics Segment by Company
Assertio Holdings, Inc
Bausch Health
Boehringer Ingelheim International GmbH
Endo International Plc
F. Hoffmann-La Roche AG
Purdue Pharmaceuticals L.P.
Sanofi S.A.
Teva Pharmaceuticals
Abbott Laboratories
Bayer AG
GlaxoSmithKline plc
Pfizer Inc.
Novartis AG
Johnson & Johnson
Opioid Analgesics Segment by Type
Morphine
Methadone
OxyContin
Vicodin
Others
Opioid Analgesics Segment by Application
Surgical Pain
Neuropathic Pain
Cancer Pain
Others
Opioid Analgesics Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Opioid Analgesics status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Opioid Analgesics market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Opioid Analgesics significant trends, drivers, influence factors in global and regions.
6. To analyze Opioid Analgesics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Opioid Analgesics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Opioid Analgesics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Opioid Analgesics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Opioid Analgesics market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Opioid Analgesics industry.
Chapter 3: Detailed analysis of Opioid Analgesics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Opioid Analgesics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Opioid Analgesics in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
More report detail
Tables and figures
Scope & coverage.
Types
- Morphine
- Methadone
- OxyContin
- Vicodin
- Others
Applications
- Surgical Pain
- Neuropathic Pain
- Cancer Pain
- Others
Companies covered
- Assertio Holdings, Inc
- Bausch Health
- Boehringer Ingelheim International GmbH
- Endo International Plc
- F. Hoffmann-La Roche AG
- Purdue Pharmaceuticals L.P.
- Sanofi S.A.
- Teva Pharmaceuticals
- Abbott Laboratories
- Bayer AG
- GlaxoSmithKline plc
- Pfizer Inc.
- Novartis AG
- Johnson & Johnson
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Opioid Analgesics Sales Value (2021-2032)
- 1.2.2 Global Opioid Analgesics Sales Volume (2021-2032)
- 1.2.3 Global Opioid Analgesics Sales Average Price (2021-2032)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
2 Opioid Analgesics Market Dynamics
- 2.1 Opioid Analgesics Industry Trends
- 2.2 Opioid Analgesics Industry Drivers
- 2.3 Opioid Analgesics Industry Opportunities and Challenges
- 2.4 Opioid Analgesics Industry Restraints
3 Opioid Analgesics Market by Company
- 3.1 Global Opioid Analgesics Company Revenue Ranking in 2025
- 3.2 Global Opioid Analgesics Revenue by Company (2021-2026)
- 3.3 Global Opioid Analgesics Sales Volume by Company (2021-2026)
- 3.4 Global Opioid Analgesics Average Price by Company (2021-2026)
- 3.5 Global Opioid Analgesics Company Ranking (2024-2026)
- 3.6 Global Opioid Analgesics Company Manufacturing Base and Headquarters
- 3.7 Global Opioid Analgesics Company Product Type and Application
- 3.8 Global Opioid Analgesics Company Establishment Date
- 3.9 Market Competitive Analysis
- 3.9.1 Global Opioid Analgesics Market Concentration Ratio (CR5 and HHI)
- 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.9.3 2025 Opioid Analgesics Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion
4 Opioid Analgesics Market by Type
- 4.1 Opioid Analgesics Type Introduction
- 4.1.1 Morphine
- 4.1.2 Methadone
- 4.1.3 OxyContin
- 4.1.4 Vicodin
- 4.1.5 Others
- 4.2 Global Opioid Analgesics Sales Volume by Type
- 4.2.1 Global Opioid Analgesics Sales Volume by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Opioid Analgesics Sales Volume by Type (2021-2032)
- 4.2.3 Global Opioid Analgesics Sales Volume Share by Type (2021-2032)
- 4.3 Global Opioid Analgesics Sales Value by Type
- 4.3.1 Global Opioid Analgesics Sales Value by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Opioid Analgesics Sales Value by Type (2021-2032)
- 4.3.3 Global Opioid Analgesics Sales Value Share by Type (2021-2032)
5 Opioid Analgesics Market by Application
- 5.1 Opioid Analgesics Application Introduction
- 5.1.1 Surgical Pain
- 5.1.2 Neuropathic Pain
- 5.1.3 Cancer Pain
- 5.1.4 Others
- 5.2 Global Opioid Analgesics Sales Volume by Application
- 5.2.1 Global Opioid Analgesics Sales Volume by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Opioid Analgesics Sales Volume by Application (2021-2032)
- 5.2.3 Global Opioid Analgesics Sales Volume Share by Application (2021-2032)
- 5.3 Global Opioid Analgesics Sales Value by Application
- 5.3.1 Global Opioid Analgesics Sales Value by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Opioid Analgesics Sales Value by Application (2021-2032)
- 5.3.3 Global Opioid Analgesics Sales Value Share by Application (2021-2032)
6 Opioid Analgesics Regional Sales and Value Analysis
- 6.1 Global Opioid Analgesics Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Opioid Analgesics Sales by Region (2021-2032)
- 6.2.1 Global Opioid Analgesics Sales by Region: 2021-2026
- 6.2.2 Global Opioid Analgesics Sales by Region (2027-2032)
- 6.3 Global Opioid Analgesics Sales Value by Region: 2021 VS 2025 VS 2032
- 6.4 Global Opioid Analgesics Sales Value by Region (2021-2032)
- 6.4.1 Global Opioid Analgesics Sales Value by Region: 2021-2026
- 6.4.2 Global Opioid Analgesics Sales Value by Region (2027-2032)
- 6.5 Global Opioid Analgesics Market Price Analysis by Region (2021-2026)
- 6.6 North America
- 6.6.1 North America Opioid Analgesics Sales Value (2021-2032)
- 6.6.2 North America Opioid Analgesics Sales Value Share by Country, 2025 VS 2032
- 6.7 Europe
- 6.7.1 Europe Opioid Analgesics Sales Value (2021-2032)
- 6.7.2 Europe Opioid Analgesics Sales Value Share by Country, 2025 VS 2032
- 6.8 Asia-Pacific
- 6.8.1 Asia-Pacific Opioid Analgesics Sales Value (2021-2032)
- 6.8.2 Asia-Pacific Opioid Analgesics Sales Value Share by Country, 2025 VS 2032
- 6.9 South America
- 6.9.1 South America Opioid Analgesics Sales Value (2021-2032)
- 6.9.2 South America Opioid Analgesics Sales Value Share by Country, 2025 VS 2032
- 6.10 Middle East & Africa
- 6.10.1 Middle East & Africa Opioid Analgesics Sales Value (2021-2032)
- 6.10.2 Middle East & Africa Opioid Analgesics Sales Value Share by Country, 2025 VS 2032
7 Opioid Analgesics Country-level Sales and Value Analysis
- 7.1 Global Opioid Analgesics Sales by Country: 2021 VS 2025 VS 2032
- 7.2 Global Opioid Analgesics Sales Value by Country: 2021 VS 2025 VS 2032
- 7.3 Global Opioid Analgesics Sales by Country (2021-2032)
- 7.3.1 Global Opioid Analgesics Sales by Country (2021-2026)
- 7.3.2 Global Opioid Analgesics Sales by Country (2027-2032)
- 7.4 Global Opioid Analgesics Sales Value by Country (2021-2032)
- 7.4.1 Global Opioid Analgesics Sales Value by Country (2021-2026)
- 7.4.2 Global Opioid Analgesics Sales Value by Country (2027-2032)
- 7.5 USA
- 7.5.1 USA Opioid Analgesics Sales Value Growth Rate (2021-2032)
- 7.5.2 USA Opioid Analgesics Sales Value Share by Type, 2025 VS 2032
- 7.5.3 USA Opioid Analgesics Sales Value Share by Application, 2025 VS 2032
- 7.6 Canada
- 7.6.1 Canada Opioid Analgesics Sales Value Growth Rate (2021-2032)
- 7.6.2 Canada Opioid Analgesics Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Canada Opioid Analgesics Sales Value Share by Application, 2025 VS 2032
- 7.7 Mexico
- 7.6.1 Mexico Opioid Analgesics Sales Value Growth Rate (2021-2032)
- 7.6.2 Mexico Opioid Analgesics Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Mexico Opioid Analgesics Sales Value Share by Application, 2025 VS 2032
- 7.8 Germany
- 7.8.1 Germany Opioid Analgesics Sales Value Growth Rate (2021-2032)
- 7.8.2 Germany Opioid Analgesics Sales Value Share by Type, 2025 VS 2032
- 7.8.3 Germany Opioid Analgesics Sales Value Share by Application, 2025 VS 2032
- 7.9 France
- 7.9.1 France Opioid Analgesics Sales Value Growth Rate (2021-2032)
- 7.9.2 France Opioid Analgesics Sales Value Share by Type, 2025 VS 2032
- 7.9.3 France Opioid Analgesics Sales Value Share by Application, 2025 VS 2032
- 7.10 U.K.
- 7.10.1 U.K. Opioid Analgesics Sales Value Growth Rate (2021-2032)
- 7.10.2 U.K. Opioid Analgesics Sales Value Share by Type, 2025 VS 2032
- 7.10.3 U.K. Opioid Analgesics Sales Value Share by Application, 2025 VS 2032
- 7.11 Italy
- 7.11.1 Italy Opioid Analgesics Sales Value Growth Rate (2021-2032)
- 7.11.2 Italy Opioid Analgesics Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Italy Opioid Analgesics Sales Value Share by Application, 2025 VS 2032
- 7.12 Spain
- 7.12.1 Spain Opioid Analgesics Sales Value Growth Rate (2021-2032)
- 7.12.2 Spain Opioid Analgesics Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Spain Opioid Analgesics Sales Value Share by Application, 2025 VS 2032
- 7.13 Russia
- 7.13.1 Russia Opioid Analgesics Sales Value Growth Rate (2021-2032)
- 7.13.2 Russia Opioid Analgesics Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Russia Opioid Analgesics Sales Value Share by Application, 2025 VS 2032
- 7.14 Netherlands
- 7.14.1 Netherlands Opioid Analgesics Sales Value Growth Rate (2021-2032)
- 7.14.2 Netherlands Opioid Analgesics Sales Value Share by Type, 2025 VS 2032
- 7.14.3 Netherlands Opioid Analgesics Sales Value Share by Application, 2025 VS 2032
- 7.15 Nordic Countries
- 7.15.1 Nordic Countries Opioid Analgesics Sales Value Growth Rate (2021-2032)
- 7.15.2 Nordic Countries Opioid Analgesics Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Nordic Countries Opioid Analgesics Sales Value Share by Application, 2025 VS 2032
- 7.16 China
- 7.16.1 China Opioid Analgesics Sales Value Growth Rate (2021-2032)
- 7.16.2 China Opioid Analgesics Sales Value Share by Type, 2025 VS 2032
- 7.16.3 China Opioid Analgesics Sales Value Share by Application, 2025 VS 2032
- 7.17 Japan
- 7.17.1 Japan Opioid Analgesics Sales Value Growth Rate (2021-2032)
- 7.17.2 Japan Opioid Analgesics Sales Value Share by Type, 2025 VS 2032
- 7.17.3 Japan Opioid Analgesics Sales Value Share by Application, 2025 VS 2032
- 7.18 South Korea
- 7.18.1 South Korea Opioid Analgesics Sales Value Growth Rate (2021-2032)
- 7.18.2 South Korea Opioid Analgesics Sales Value Share by Type, 2025 VS 2032
- 7.18.3 South Korea Opioid Analgesics Sales Value Share by Application, 2025 VS 2032
- 7.19 India
- 7.19.1 India Opioid Analgesics Sales Value Growth Rate (2021-2032)
- 7.19.2 India Opioid Analgesics Sales Value Share by Type, 2025 VS 2032
- 7.19.3 India Opioid Analgesics Sales Value Share by Application, 2025 VS 2032
- 7.20 Australia
- 7.20.1 Australia Opioid Analgesics Sales Value Growth Rate (2021-2032)
- 7.20.2 Australia Opioid Analgesics Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Australia Opioid Analgesics Sales Value Share by Application, 2025 VS 2032
- 7.21 Southeast Asia
- 7.21.1 Southeast Asia Opioid Analgesics Sales Value Growth Rate (2021-2032)
- 7.21.2 Southeast Asia Opioid Analgesics Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Southeast Asia Opioid Analgesics Sales Value Share by Application, 2025 VS 2032
- 7.22 Brazil
- 7.22.1 Brazil Opioid Analgesics Sales Value Growth Rate (2021-2032)
- 7.22.2 Brazil Opioid Analgesics Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Brazil Opioid Analgesics Sales Value Share by Application, 2025 VS 2032
- 7.23 Argentina
- 7.23.1 Argentina Opioid Analgesics Sales Value Growth Rate (2021-2032)
- 7.23.2 Argentina Opioid Analgesics Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Argentina Opioid Analgesics Sales Value Share by Application, 2025 VS 2032
- 7.24 Chile
- 7.24.1 Chile Opioid Analgesics Sales Value Growth Rate (2021-2032)
- 7.24.2 Chile Opioid Analgesics Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Chile Opioid Analgesics Sales Value Share by Application, 2025 VS 2032
- 7.25 Colombia
- 7.25.1 Colombia Opioid Analgesics Sales Value Growth Rate (2021-2032)
- 7.25.2 Colombia Opioid Analgesics Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Colombia Opioid Analgesics Sales Value Share by Application, 2025 VS 2032
- 7.26 Peru
- 7.26.1 Peru Opioid Analgesics Sales Value Growth Rate (2021-2032)
- 7.26.2 Peru Opioid Analgesics Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Peru Opioid Analgesics Sales Value Share by Application, 2025 VS 2032
- 7.27 Saudi Arabia
- 7.27.1 Saudi Arabia Opioid Analgesics Sales Value Growth Rate (2021-2032)
- 7.27.2 Saudi Arabia Opioid Analgesics Sales Value Share by Type, 2025 VS 2032
- 7.27.3 Saudi Arabia Opioid Analgesics Sales Value Share by Application, 2025 VS 2032
- 7.28 Israel
- 7.28.1 Israel Opioid Analgesics Sales Value Growth Rate (2021-2032)
- 7.28.2 Israel Opioid Analgesics Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Israel Opioid Analgesics Sales Value Share by Application, 2025 VS 2032
- 7.29 UAE
- 7.29.1 UAE Opioid Analgesics Sales Value Growth Rate (2021-2032)
- 7.29.2 UAE Opioid Analgesics Sales Value Share by Type, 2025 VS 2032
- 7.29.3 UAE Opioid Analgesics Sales Value Share by Application, 2025 VS 2032
- 7.30 Turkey
- 7.30.1 Turkey Opioid Analgesics Sales Value Growth Rate (2021-2032)
- 7.30.2 Turkey Opioid Analgesics Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Turkey Opioid Analgesics Sales Value Share by Application, 2025 VS 2032
- 7.31 Iran
- 7.31.1 Iran Opioid Analgesics Sales Value Growth Rate (2021-2032)
- 7.31.2 Iran Opioid Analgesics Sales Value Share by Type, 2025 VS 2032
- 7.31.3 Iran Opioid Analgesics Sales Value Share by Application, 2025 VS 2032
- 7.32 Egypt
- 7.32.1 Egypt Opioid Analgesics Sales Value Growth Rate (2021-2032)
- 7.32.2 Egypt Opioid Analgesics Sales Value Share by Type, 2025 VS 2032
- 7.32.3 Egypt Opioid Analgesics Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 Assertio Holdings, Inc
- 8.1.1 Assertio Holdings, Inc Company Information
- 8.1.2 Assertio Holdings, Inc Business Overview
- 8.1.3 Assertio Holdings, Inc Opioid Analgesics Sales, Value and Gross Margin (2021-2026)
- 8.1.4 Assertio Holdings, Inc Opioid Analgesics Product Portfolio
- 8.1.5 Assertio Holdings, Inc Recent Developments
- 8.2 Bausch Health
- 8.2.1 Bausch Health Company Information
- 8.2.2 Bausch Health Business Overview
- 8.2.3 Bausch Health Opioid Analgesics Sales, Value and Gross Margin (2021-2026)
- 8.2.4 Bausch Health Opioid Analgesics Product Portfolio
- 8.2.5 Bausch Health Recent Developments
- 8.3 Boehringer Ingelheim International GmbH
- 8.3.1 Boehringer Ingelheim International GmbH Company Information
- 8.3.2 Boehringer Ingelheim International GmbH Business Overview
- 8.3.3 Boehringer Ingelheim International GmbH Opioid Analgesics Sales, Value and Gross Margin (2021-2026)
- 8.3.4 Boehringer Ingelheim International GmbH Opioid Analgesics Product Portfolio
- 8.3.5 Boehringer Ingelheim International GmbH Recent Developments
- 8.4 Endo International Plc
- 8.4.1 Endo International Plc Company Information
- 8.4.2 Endo International Plc Business Overview
- 8.4.3 Endo International Plc Opioid Analgesics Sales, Value and Gross Margin (2021-2026)
- 8.4.4 Endo International Plc Opioid Analgesics Product Portfolio
- 8.4.5 Endo International Plc Recent Developments
- 8.5 F. Hoffmann-La Roche AG
- 8.5.1 F. Hoffmann-La Roche AG Company Information
- 8.5.2 F. Hoffmann-La Roche AG Business Overview
- 8.5.3 F. Hoffmann-La Roche AG Opioid Analgesics Sales, Value and Gross Margin (2021-2026)
- 8.5.4 F. Hoffmann-La Roche AG Opioid Analgesics Product Portfolio
- 8.5.5 F. Hoffmann-La Roche AG Recent Developments
- 8.6 Purdue Pharmaceuticals L.P.
- 8.6.1 Purdue Pharmaceuticals L.P. Company Information
- 8.6.2 Purdue Pharmaceuticals L.P. Business Overview
- 8.6.3 Purdue Pharmaceuticals L.P. Opioid Analgesics Sales, Value and Gross Margin (2021-2026)
- 8.6.4 Purdue Pharmaceuticals L.P. Opioid Analgesics Product Portfolio
- 8.6.5 Purdue Pharmaceuticals L.P. Recent Developments
- 8.7 Sanofi S.A.
- 8.7.1 Sanofi S.A. Company Information
- 8.7.2 Sanofi S.A. Business Overview
- 8.7.3 Sanofi S.A. Opioid Analgesics Sales, Value and Gross Margin (2021-2026)
- 8.7.4 Sanofi S.A. Opioid Analgesics Product Portfolio
- 8.7.5 Sanofi S.A. Recent Developments
- 8.8 Teva Pharmaceuticals
- 8.8.1 Teva Pharmaceuticals Company Information
- 8.8.2 Teva Pharmaceuticals Business Overview
- 8.8.3 Teva Pharmaceuticals Opioid Analgesics Sales, Value and Gross Margin (2021-2026)
- 8.8.4 Teva Pharmaceuticals Opioid Analgesics Product Portfolio
- 8.8.5 Teva Pharmaceuticals Recent Developments
- 8.9 Abbott Laboratories
- 8.9.1 Abbott Laboratories Company Information
- 8.9.2 Abbott Laboratories Business Overview
- 8.9.3 Abbott Laboratories Opioid Analgesics Sales, Value and Gross Margin (2021-2026)
- 8.9.4 Abbott Laboratories Opioid Analgesics Product Portfolio
- 8.9.5 Abbott Laboratories Recent Developments
- 8.10 Bayer AG
- 8.10.1 Bayer AG Company Information
- 8.10.2 Bayer AG Business Overview
- 8.10.3 Bayer AG Opioid Analgesics Sales, Value and Gross Margin (2021-2026)
- 8.10.4 Bayer AG Opioid Analgesics Product Portfolio
- 8.10.5 Bayer AG Recent Developments
- 8.11 GlaxoSmithKline plc
- 8.11.1 GlaxoSmithKline plc Company Information
- 8.11.2 GlaxoSmithKline plc Business Overview
- 8.11.3 GlaxoSmithKline plc Opioid Analgesics Sales, Value and Gross Margin (2021-2026)
- 8.11.4 GlaxoSmithKline plc Opioid Analgesics Product Portfolio
- 8.11.5 GlaxoSmithKline plc Recent Developments
- 8.12 Pfizer Inc.
- 8.12.1 Pfizer Inc. Company Information
- 8.12.2 Pfizer Inc. Business Overview
- 8.12.3 Pfizer Inc. Opioid Analgesics Sales, Value and Gross Margin (2021-2026)
- 8.12.4 Pfizer Inc. Opioid Analgesics Product Portfolio
- 8.12.5 Pfizer Inc. Recent Developments
- 8.13 Novartis AG
- 8.13.1 Novartis AG Company Information
- 8.13.2 Novartis AG Business Overview
- 8.13.3 Novartis AG Opioid Analgesics Sales, Value and Gross Margin (2021-2026)
- 8.13.4 Novartis AG Opioid Analgesics Product Portfolio
- 8.13.5 Novartis AG Recent Developments
- 8.14 Johnson & Johnson
- 8.14.1 Johnson & Johnson Company Information
- 8.14.2 Johnson & Johnson Business Overview
- 8.14.3 Johnson & Johnson Opioid Analgesics Sales, Value and Gross Margin (2021-2026)
- 8.14.4 Johnson & Johnson Opioid Analgesics Product Portfolio
- 8.14.5 Johnson & Johnson Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Opioid Analgesics Value Chain Analysis
- 9.1.1 Opioid Analgesics Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Opioid Analgesics Sales Mode & Process
- 9.2 Opioid Analgesics Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Opioid Analgesics Distributors
- 9.2.3 Opioid Analgesics Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst